Today, many in the general public are not aware that there are effective interventions to slow the progression of myopia in children. In fact, before we started supporting a company at the forefront of these new technologies, we too were unaware of the availability of such therapies.
Most ECPs still only offer corrective lenses to treat myopia and don’t even discuss options that fall within the the category of “myopia management” and are essentially disease modifying. Low single digits of ECPs are offering myopia management in children.
As a parent I wish I was offered the choice for my daughter to slow her progression the first time she was diagnosed with myopia. At the moment, there is no national or global clinical practice guidelines for treating myopia even though products are approved in multiple countries to treat myopia in children.
Science is ahead of the medical and advocacy organizations; much work needs to be done.
Snowfish has worked for over two decades to connect the dots within the three important stakeholder categories: patients, clinicians and organizations.
It is critical to identify patients that could benefit from new treatments. This involves defining patient attributes and how they receive information from their own influencers including advocacy and support groups.
All of the various inputs are cataloged so our clients can improve the outreach efforts. At times this involves hundreds of unique inputs that allow for micro targeting.
Data are married up to the clinicians that are at the forefront of the disease. By identifying the leading key opinion leader (KOL) and the Centers of Excellence (CoEs), we empower companies with cutting-edge therapies to connect with patients and clinicians.
We also identify KOLs working with association and advocacy groups so that engagement can be leveraged through those channels.
Professional associations promulgate clinical practice guidelines which are foundational to the practice of medicine.
Snowfish will analyze dozens of associations based on multiple factors such as their views regarding a given treatment, key people, publication and social media, constituents, relationships with industry, and collaboration with other organizations. This enables our clients to develop a winning engagement plan with a select group.
The life science industry is constantly evolving. It takes an ongoing and sustain engagement strategy with patients, clinicians, and organizations to make an impact.